Denali Therapeutics (NASDAQ:DNLI - Free Report) had its price objective decreased by Bank of America from $30.00 to $28.00 in a report issued on Monday,Benzinga reports. Bank of America currently has a buy rating on the stock.
DNLI has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective on the stock. The Goldman Sachs Group cut their price objective on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. William Blair reissued an "outperform" rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Robert W. Baird began coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target on the stock. Finally, B. Riley reissued a "buy" rating and issued a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Denali Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $37.20.
View Our Latest Stock Report on Denali Therapeutics
Denali Therapeutics Price Performance
DNLI traded up $0.25 during midday trading on Monday, hitting $15.14. 15,843 shares of the company's stock traded hands, compared to its average volume of 1,007,537. The company has a market cap of $2.20 billion, a PE ratio of -5.50 and a beta of 1.46. The stock's fifty day simple moving average is $20.38 and its 200-day simple moving average is $24.05. Denali Therapeutics has a one year low of $14.01 and a one year high of $33.33.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.08. On average, research analysts expect that Denali Therapeutics will post -2.71 EPS for the current year.
Insiders Place Their Bets
In other news, insider Carole Ho sold 12,255 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the sale, the insider now owns 178,580 shares in the company, valued at approximately $3,610,887.60. The trade was a 6.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 3,080 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares in the company, valued at $2,257,778.16. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock worth $973,442 over the last 90 days. Corporate insiders own 7.90% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Polar Asset Management Partners Inc. raised its holdings in shares of Denali Therapeutics by 1,240.9% in the fourth quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company's stock valued at $11,231,000 after buying an additional 509,992 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Denali Therapeutics in the fourth quarter valued at about $62,000. Woodline Partners LP bought a new position in shares of Denali Therapeutics in the fourth quarter valued at about $2,038,000. Squarepoint Ops LLC raised its holdings in shares of Denali Therapeutics by 44.2% in the fourth quarter. Squarepoint Ops LLC now owns 48,619 shares of the company's stock valued at $991,000 after buying an additional 14,896 shares during the last quarter. Finally, Twinbeech Capital LP bought a new position in shares of Denali Therapeutics in the fourth quarter valued at about $5,188,000. 92.92% of the stock is owned by institutional investors.
About Denali Therapeutics
(
Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Read More

Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.